技术与方法 |
|
|
|
|
质谱方法实现抗体类药物糖链修饰的鉴定与定量研究 |
黄怡1,2,李晓宇2,田芳2,钱小红2,应万涛1,2() |
1 安徽医科大学 合肥 230032 2 蛋白质组学国家重点实验室 北京蛋白质组学研究中心 国家蛋白质科学中心军事医学科学院放射与辐射医学研究所 北京 102206 |
|
Identification and Quantitative Study on Glycosylation Chain Modification of Antibody Drugs by Mass Spectrometry |
Yi HUANG1,2,Xiao-yu LI2,Fang TIAN2,Xiao-hong QIAN2,Wan-tao YING1,2() |
1 Anhui Medical University,Hefei 230032,China 2 State Key Laboratory of Proteomics, Beijing Proteome Research Center,National Center for Protein Science,Beijing Institute of Radiation Medicine, Beijing 102206,China |
引用本文:
黄怡,李晓宇,田芳,钱小红,应万涛. 质谱方法实现抗体类药物糖链修饰的鉴定与定量研究[J]. 中国生物工程杂志, 2018, 38(1): 32-41.
Yi HUANG,Xiao-yu LI,Fang TIAN,Xiao-hong QIAN,Wan-tao YING. Identification and Quantitative Study on Glycosylation Chain Modification of Antibody Drugs by Mass Spectrometry. China Biotechnology, 2018, 38(1): 32-41.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20180104
或
https://manu60.magtech.com.cn/biotech/CN/Y2018/V38/I1/32
|
[1] |
翁锦玉. 国际生物医药产业发展趋势分析.科技与创新,2017, 1(1): 1-2.
|
|
Weng J Y.Analysis of international biomedical industry development trend . Science and Technology & Innovation,2017, 1(1): 1-2.
|
[2] |
刘艳玲,刘晓志,赵伟,等.糖蛋白药物的多糖结构解析进展.生物技术进展,2016, 6(4): 244-248.
|
|
Liu Y L,Liu X Z, Zhao W, et al.Progress on glycan analysis of therapeutic glycoprotein . Current Biotechnology,2016, 6(4): 244-248.
|
[3] |
Yang X,Kim S M,Ruzanski R,et al.Μltrafast and high-throughput N-glycan analysis for monoclonal antibodies.MAbs Taylor & Francis,2016, 8(4): 706-717.
|
[4] |
Reusch D, Haberger M, Maier B, et al.Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-part 1:Separation-based methods.MAbs Taylor & Francis,2015, 7(1): 167-179.
doi: 10.4161/19420862.2014.986000
pmid: 25524468
|
[5] |
Yang N,Goonatilleke E,Park D,et al.Quantitation of site-specific glycosylation in manufactured recombinant monoclonal antibody drugs. Analytical Chemistry,2016, 88(14): 7091-7100.
doi: 10.1021/acs.analchem.6b00963
pmid: 4955800
|
[6] |
Planinc A,Dejaegher B,Vander Heyden Y,et al. Batch-to-batch N-glycosylation study of infliximab, trastuzumab and bevacizumab, and stability study of bevacizumab. Eur J Hosp Pharm,2017, 24(5): 286-292.
|
[7] |
Sanchez-De Melo I,Grassi P,Ochoa F,et al. N-glycosylation profile analysis of trastuzumab biosimilar candidates by normal phase liquid chromatography and MALDI-TOF MS approaches . Journal of Proteomics,2015, 127: 225-233.
doi: 10.1016/j.jprot.2015.04.012
pmid: 25907685
|
[8] |
任跃明. 国内外生物技术类制品质量标准差异浅析. 中国执业药师, 2012, 9(9): 60-64.
doi: 10.3969/j.issn.1672-5433.2012.09.012
|
|
Ren Y M.Discussion on the official standards of biotechnological products in Chinese and European Pharmacopeias.China Licensed Pharmacist, 2012, 9(9): 60-64.
doi: 10.3969/j.issn.1672-5433.2012.09.012
|
[9] |
高凯, 徐志凯, 任跃明, 等. 关于我国药典单克隆抗体类生物治疗药物总论的思考. 中国生物工程杂志, 2014, 34(1): 127-134.
doi: 10.13523/j.cb.20140117
|
|
Gao K, Xu Z K, Ren Y M, et al.Points to consider for the general monograph of monoclonal antibody based biotherapeutics in chinese pharamacopeia .China Biotechnology, 2014, 34(1): 127-134.
doi: 10.13523/j.cb.20140117
|
[10] |
Liu M Q, Zeng W F, Fang P, et al.pGlyco 2.0 enables precision N-glycoproteomics with comprehensive quality control and one-step mass spectrometry for intact glycopeptide identification. Nature Communications, 2017, 8(1): 438.
doi: 10.1038/s41467-017-00535-2
pmid: 5585273
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|